1,4-Butanediol

1,4-Butanediol

SCHEMBL5836779

O=C(O)Cl.O=C(O)Cl.OCCCCO

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 1/20 0.53
FFAR1 O14842 1/20 0.53
FFAR4 Q5NUL3 1/20 0.53
CAMK2A Q9UQM7 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.39
FNTA P49354 1/20 0.39
FNTB P49356 1/20 0.39
LMNA P02545 4/20 0.37
TSHR P16473 4/20 0.37
ALDH1A1 P00352 3/20 0.37
HSD17B10 Q99714 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
KDM4E B2RXH2 1/20 0.36
ARG2 P78540 1/20 0.33
SLC22A6 Q4U2R8 1/20 0.33
TP53 P04637 1/20 0.32
OR51E2 Q9H255 1/20 0.32
NFKB1 P19838 1/20 0.32
PMP22 Q01453 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
1,4-Butanediol SCHEMBL9581258 1.00 GPR84 (0.53) GPR84FFAR1FFAR4CAMK2ASMN1; SMN2
1,6-Hexanediol SCHEMBL5836918 0.96 GPR84 (0.58) GPR84FFAR1FFAR4CAMK2ASMN1; SMN2
1,4-Butanediol SCHEMBL10945004 0.88 GPR84 (0.47) GPR84FFAR1FFAR4CAMK2ASMN1; SMN2
1,6-Hexanediol SCHEMBL3100208 0.85 GPR84 (0.53) GPR84FFAR1FFAR4CAMK2ASMN1; SMN2
Ethylene Glycol SCHEMBL3087642 0.84 TSHR (0.46) GPR84FFAR1FFAR4CAMK2ALMNA
Ethylene Glycol SCHEMBL4958765 0.84 TSHR (0.46) GPR84FFAR1FFAR4CAMK2ALMNA
Ethylene Glycol SCHEMBL9313825 0.84
1,4-Butanediol SCHEMBL575106 0.84 GPR84 (0.59) GPR84FFAR1FFAR4CAMK2ASMN1; SMN2
Cetyl Alcohol SCHEMBL21876446 0.83 TSHR (0.68) GPR84FFAR1FFAR4SMN1; SMN2LMNA
1,4-Butanediol SCHEMBL2025239 0.81 GPR84 (0.43) GPR84FFAR1FFAR4CAMK2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373633-B1 METHOD FOR PRODUCING TRAZINE CARBAMATES USING CHLOROFORMATES BOREALIS AGROLINZ MELAMINE (AT) 2014-04-16 EP claimed
US-20110295001-A1 Method for Producing Triazine Carbamates Using Chloroformates BOREALIS AGROLINZ MELAMINE GMBH (AT) 2011-12-01 US claimed
US-20250302760-A1 BIODEGRADABLE, CONTROLLED RELEASE MICROCAPSULES ENCAPSYS, LLC (US) 2025-10-02 US disclosed
US-20110295001-A1 Method for Producing Triazine Carbamates Using Chloroformates BOREALIS AGROLINZ MELAMINE GMBH (AT) 2011-12-01 US disclosed
US-7078553-B2 Dehydrohalogenation by reacting a di-hydroperoxy compound with an acid halogen or halogen formate to form mono- or di-peroxy ester or carbonate; polymerization initiators, curing agents for unsaturated polyesters and modifying agents AKZO NOBEL N.V. (NL) 2006-07-18 US disclosed
US-20040260111-A1 Dehydrohalogenation by reacting a di-hydroperoxy compound with an acid halogen or halogen formate to form mono- or di-peroxy ester or carbonate; polymerization initiators, curing agents for unsaturated polyesters and modifying agents VAN DE BOVENKAMP-BOUWMAN ANNA (NL) 2004-12-23 US disclosed
EP-1071662-B1 PEROXIDES, THEIR PREPARATION PROCESS AND USE AKZO NOBEL NV (NL) 2004-08-04 EP disclosed
US-6770774-B2 USING A PEROXY COMPOUND AS CURING AGENT, POLYMERIZATION CATALYST AKZO NOBEL N.V. (NL) 2004-08-03 US disclosed
US-6552215-B1 Reacting a hydroperoxy compound containing a peroxyester or peroxycarbonate functionality with an alkyl vinyl ether; polymerization initiators, curing agents for unsaturated polyesters and modifying agents AKZO NOBEL N.V. (NL) 2003-04-22 US disclosed
US-20030073861-A1 Using a peroxy compound as curing agent, polymerization catalyst VAN DE BOVENKAMP-BOUWMAN ANNA (NL) 2003-04-17 US disclosed
EP-1049668-B1 KETONE PEROXIDE DERIVATIVES, THEIR PREPARATION AND USE AKZO NOBEL NV (NL) 2003-03-19 EP disclosed
US-6482970-B1 Peroxides, their preparation process and use AKZO NOBEL NV (NL) 2002-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040260111-A1 Dehydrohalogenation by reacting a di-hydroperoxy compound with an acid halogen or halogen formate to form mono- or di-peroxy ester or carbonate; polymerization initiators, curing agents for unsaturated polyesters and modifying agents GPX4, HDHD5, HAO2 GPR84 2989/4885FFAR1 778/4885FFAR4 622/4885
US-20110295001-A1 Method for Producing Triazine Carbamates Using Chloroformates CA3, CA7, KAT5 GPR84 2460/4885FFAR1 3219/4885FFAR4 3047/4885
US-20030073861-A1 Using a peroxy compound as curing agent, polymerization catalyst PRDX4, ACOX3, PRDX2 GPR84 2103/4885FFAR1 523/4885FFAR4 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.